Sato T, Nara Y, Note S, Yamori Y
Metabolism. 1987 Aug;36(8):731-7. doi: 10.1016/0026-0495(87)90108-9.
Hypertensive diabetic animal models have been developed by injecting streptozotocin (STZ) in neonatal stroke-resistant spontaneously hypertensive rats (SHRSR) and stroke-prone SHR (SHRSP) at the age of two days. After the treatment, the animals showed mild insulin deficiency and mild hyperglycemia at the age of three to four months. Diabetic nephropathy was produced particularly in STZ-treated SHRSR at the age of six months. The effect of neonatal STZ injection on hyperglycemia varied among normotensive Wistar-Kyoto rats (WKY), SHRSR, and SHRSP; SHRSR showed the highest glucose levels, SHRSP showed intermediate levels, and WKY was the lowest. All STZ-treated SHRSR showed glycosuria, while glycosuria was not observed in the treated SHRSP and WKY. Histologic study indicated that these strain differences were partly ascribed to differences in islet B-cell sensitivity to toxic effects of STZ. The development of hypertension was not accelerated in these SHRSR and SHRSP compared with respective nontreated controls. Since STZ-treated SHRSR develop mild diabetic symptom with hypertension and develop mild diabetic glomerulosclerosis, they are good models for studying vascular complications or other problems relating to the synergism between hypertension and diabetes mellitus.
通过在出生两天的抗中风自发性高血压大鼠（SHRSR）和易中风自发性高血压大鼠（SHRSP）中注射链脲佐菌素（STZ），建立了高血压糖尿病动物模型。治疗后，这些动物在三到四个月大时出现轻度胰岛素缺乏和轻度高血糖。糖尿病肾病尤其在六个月大的经STZ治疗的SHRSR中产生。新生期注射STZ对正常血压的Wistar-Kyoto大鼠（WKY）、SHRSR和SHRSP高血糖的影响各不相同；SHRSR的血糖水平最高，SHRSP处于中等水平，WKY最低。所有经STZ治疗的SHRSR均出现糖尿，而经治疗的SHRSP和WKY未观察到糖尿。组织学研究表明，这些品系差异部分归因于胰岛B细胞对STZ毒性作用的敏感性差异。与各自未治疗的对照组相比，这些SHRSR和SHRSP中高血压的发展并未加速。由于经STZ治疗的SHRSR会出现伴有高血压的轻度糖尿病症状，并发展为轻度糖尿病肾小球硬化，因此它们是研究血管并发症或其他与高血压和糖尿病协同作用相关问题的良好模型。
